Caline Sakabedoyan

LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

María‐Victoria Mateos, Katja Weisel, Valerio De Stefano et al. · Leukemia · 2022 · 225 citations · Full text

Relapsed/refractory Mm, Cancer Management, Immunology +18

Self-Renewal of Murine Embryonic Stem Cells Is Supported by the Serine/Threonine Kinases Pim-1 and Pim-3

Irène Aksoy, Caline Sakabedoyan, Pierre-Yves Bourillot et al. · Stem Cells · 2007 · 68 citations · Full text

Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial

Marc S. Raab, Niels Weinhold, K. Martin Kortüm et al. · Blood · 2024 · 31 citations

MajesTEC-4 (EMN30): A Phase 3 Trial of Teclistamab + Lenalidomide Versus Lenalidomide Alone As Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma

Elena Zamagni, Mario Boccadoro, Andrew Spencer et al. · Blood · 2022 · 27 citations

Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial

Elena Zamagni, Tobias Silzle, Ivan Špıčka et al. · Blood · 2024 · 18 citations · Full text